Royalty Report: Drugs, Cancer, Therapeutic – Collection: 209522

License Grant

Licensor grants a non-exclusive, non-transferable license under the Licensed Technology to make and have made, use and sell Licensed Products and to use the Licensed Technology, in each case in the Field in the Territory.

Licensor grants an option to include under the License any or all of the peptides listed, together with all associated patents and patent applications listed, as applicable, and any corresponding foreign counterparts thereof, and all patents issuing thereon, including any division, continuation, continuation-in-part or substitution of any such patent application, and any reissue, extension, confirmation, registration, re-examination or inventors certificate of any such patent, together with any corresponding foreign counterparts of the foregoing.

Licensor grants an irrevocable option to include Japan in the Territory if Licensor regains rights to the Licensed Technology in the Field in Japan.

License Property

The licensed product shall mean any product that contains, incorporates, or uses any Licensed Technology.

The licensed technology shall mean, collectively, the Licensed Patent Rights and Licensed Know-How.

The licensed know-how is
PADRE-specific HTL cell line and cell line for restimulation
Protocols for restimulation and testing of PADRE HTL line
Non-GMP peptides (PADRE, MAGE3.112I5, MAGE2.157)
Epitope-specific CTL cell lines (as available) and protocols for use Formulation development data for BCL-A2 peptides

Field of Use

The field shall mean (a) ex vivo therapeutic applications in cancer; (b) applications for the purpose of selecting and monitoring patients with cancer and the treatment of such patients, in either case of (a) or (b) where such applications involve the use of dendritic cells or other antigen-presenting cells, immortalized cells or exosomes produced by any of the foregoing cells to produce or modulate a human immune system response to cancer; and (c) ex vivo therapeutic use of synthetic exosomes to produce or modulate a human immune system response to cancer.

License Grant

Licensor grants to the French Licensee a non-exclusive license to make and have made, including the right to make derivatives, and to use the Licensed Technology and to make, have made, use, sell, offer for sale and import Licensed Products in the Field of Use in the Territory during the term of this Agreement the License.

For the Peptide License Option, Licensor grants a non-exclusive option, the Peptide Option, to include under the License any or all of the peptides listed hereto, the Specified Peptides, together with all associated patents and patent applications for BCL-A1 Candidates, BCL-A3 Supertype Candidates, BCL-A24 Candidates, and, BCL-B7 Supertype Candidates, as applicable, and any corresponding foreign counterparts thereof, and all patents issuing thereon, including utility, model and design patents and certificates of invention, including any division, continuation, continuation-in-part or substitution of any such patent application, and any reissue, extension, confirmation, registration, re-examination or inventors certificate of any such patent, together with any corresponding foreign counterparts of the foregoing, collectively, the Additional Rights.  

For the Japan Option, Licensor grants an irrevocable option, the Japan Option, to include Japan in the Territory. The Japan Option may be exercised at any time during the term of this Agreement.

For the New Peptide Sequences, Licensor may upon its sole discretion offer for license to Licensee any new peptide sequence together with all associated patents and patent applications owned or licensed by Licensor.

License Property

The licensed materials relate to amino butyric acid and cyclohexalanine.

Field of Use

The Field of Use shall mean ex vivo cell therapy and ex vivo cell therapy for the prevention and treatment of cancer for the peptides for which Licensor is a licensee.

License Grant

The University grants an exclusive worldwide license under the patent rights and know-how to make, have made, use, import, offer to sell, sell, offer to provide and provide Licensed Products. Such license is worldwide.  The University grants an exclusive option to obtain an exclusive, worldwide license to all new optioned inventions.

License Property

The property is referred to as Licensors 1101 Invention or the 1215 Invention.  The patented invention relates to Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA.  The inventions are detailed in patent applications #08/517,373, #08/700,035, #96/13,457 and also #08/640,444, and continuation applications.

Field of Use

The field shall mean all uses of the know-how and patent rights, cell lines, substances and material produced by cell lines and included in Patent Rights, specifically including, without limitation, research and development, diagnosis, prevention, therapy, and monitoring of all human and animal diseases or disorders, including  autoimmune diseases or disorders, infectious diseases or cancer in humans or animals.

License Grant

Licensor grants to the Licensee of Denmark a non-exclusive, non-transferable, worldwide, royalty-bearing license, with the right to grant sublicenses, under the Licensed Technology to make, have made, sell, have sold and import Products in the Field during the Term. For avoidance of doubt, Licensee shall only have the right under the license granted to use PADRE® as part of a Product.

Licensee shall have the right to grant sublicenses.

License Property

Licensed Technology shall mean, to the extent necessary or useful for research, development, manufacture, use, sale or import of Products in the Field, all Patent Rights and Know-How, including all PADRE® Improvements.

PADRE® shall mean a peptide capable of binding antigen binding sites on major histocompatibility complex (MHC) molecules encoded by substantially all alleles of a DR locus, including, without limitation, a composition comprising a peptide recited in the claims of United States Patent Application Serial No. 08/121,101 and any patent applications, U.S., international and foreign, that derive priority from such patent application, such as continuing applications and any patents issuing therefrom. Such peptides are also referred to as pan DR binding peptides and include, without limitation, AKXV AA WTLKAAA,using the single letter designation for amino acids, wherein X is cyclohexylalanine or phenylalanine, and other peptides claimed and/or disclosed in the patent applications.

Product shall mean any product that contains, is comprised of or uses PADRE® in combination or association with any AutoVac™ Molecule.

Field of Use

Field shall mean the prevention and/or treatment of diseases or disorders in humans.

The license is to use PADRE technology for use in connection with their AutoVacâ„¢ technology for controlling autoimmune diseases.
The PADRE technology consists of a family of small (13 amino acid), synthetic proprietary molecules that are potent immunostimulants, meaning that they stimulate the immune response.